Lutetium (177Lu) Vipivotide Tetraxetan

• STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer Pending
  2025-522145-21-00 Phase III 3 countries University College London
• A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSM… Recruiting
  2025-521859-23-00 Phase I/II 4 countries Novartis Pharma AG
• Radiopharmaceutical treatment of advanced kidney cancer Recruiting
  2024-517899-38-00 Phase II 3 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
• ReaLuP : Study on Re-treatment with Radiopharmaceutical Drug [177Lu]Lu-PSMA in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
  2024-512043-22-00 Phase II 1 country Hospices Civils De Lyon
• 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment with locoregion… Recruiting
  2023-504912-13-00 Phase II 1 country Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Bada…
• A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxeta… Recruiting
  2024-512338-13-00 Phase I (Other) 3 countries Novartis Pharma AG
• A Phase I/II Study of Neoadjuvant, Intra-arterial Administration of [177Lu]Lu-PSMA-617 in Subjects with High-risk, Localised or Locally Adva… Recruiting
  2022-500838-28-00 Phase I/II 1 country Universitaetsklinikum Essen AöR
• Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting
  2022-502408-57-00 Phase III 6 countries Unicancer
• An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617… Recruiting
  2022-502956-29-00 Phase III 11 countries Novartis Pharma AG
• A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa… Recruiting
  2023-503208-94-00 Phase IV 9 countries Novartis Pharma AG
• A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxeta… Ended
  2024-520155-24-00 Phase II 7 countries Novartis Pharma AG
• An Open-label Dosimetry, Tolerability and Safety Study of lutetium (177Lu) vipivotide tetraxetan in Patients with Progressive PSMA-Positive … Ended
  2023-503925-20-00 Phase II 4 countries Novartis Pharma AG
• An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended
  2022-503040-41-00 Phase II 7 countries Novartis Pharma AG
• PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therap… Ended
  2023-507772-50-00 Phase III 9 countries Novartis Pharma AG
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended
  2023-507970-42-00 Phase III 10 countries Novartis Pharma AG
• Neoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI) Ended
  2024-514386-19-00 Phase I (Other) 1 country Universitaetsklinikum Essen AöR
• A dosimetry study of lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metas… Ended
  2024-515264-31-00 Phase I (Other) 4 countries Blue Earth Therapeutics Limited
• Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer. Ended
  2023-509881-39-00 Phase II 2 countries Stichting Radboud University Medical Center
• The evaluation of the effectiveness, safety and tolerability of treatment, using a specialized prostate-specific membrane antigen (PSMA) lab… Ended
  2023-504699-73-00 Phase II 1 country Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Bada…

Showing 1–19 of 19 trials